Therapeutic equivalence evaluation of bioequivalent and original micronized vaginal progesterone preparations in hormone replacement therapy in women undergoing frozen-thawed embryo transfer
- Authors: Bashmakova N.V.1, Khramtsova A.Y.1, Dzhalilova E.R.1
-
Affiliations:
- Urals Scientific Research Institute for Maternal and Child Care, Ministry of Health of Russia
- Issue: No 9 (2023)
- Pages: 164-169
- Section: Exchange of Experience
- URL: https://journals.eco-vector.com/0300-9092/article/view/622980
- DOI: https://doi.org/10.18565/aig.2023.197
- ID: 622980
Cite item
Open Access
Access granted
Abstract
There is currently no evidence for the clinical benefits of using bioequivalent micronized progesterone preparation produced in Russia compared to the original preparation for post-transfer support after the frozen-thawed embryo transfer. Therefore, it is important to confirm the therapeutic equivalence of the Russian preparation in the programs of assisted reproductive technologies (ART).
Objective: To perform a comparative analysis of the effectiveness of frozen-thawed embryo transfer programs and pregnancy outcomes in women who took bioequivalent and original micronized vaginal progesterone preparations for the secretory transformation of the endometrium and post-transfer support.
Materials and methods: The study included 93 infertile women who had frozen-thawed own embryo transfer with hormone replacement therapy cycle in the Assisted Reproduction Department, Urals Scientific Research Institute for Maternal and Child Care. The first group consisted of 45 patients who took Russian bioequivalent micronized progesterone preparation “DlyJens pro” (600 mg/day intravaginally) for full secretory transformation of the endometrium, the second group included 48 patients who were prescribed original micronized vaginal progesterone preparation (600 mg/day intravaginally).
Results: The implantation rate was 22/45 (48.89%) patients in group 1, it was 21/48 (43.75%) in group 2. The clinical pregnancy rate was higher in group of patients who took the bioequivalent micronized progesterone preparation than in group 2 and it was 19/45 (42.22%), however, no statistical differences were found (p=0.796). There was no statistical difference in the rate of multiple pregnancies in both groups (p=0.462). Multiple pregnancies were detected in 4/19 (21%) patients in group 1 and in 6/19 (31.6%) patients in group 2.
Conclusion: The data obtained in the study on the outcomes of frozen-thawed embryo transfer programs showed comparable effectiveness of the bioequivalent and original micronized progesterone preparations. The study demonstrated the possibility of using both original and bioequivalent micronized vaginal progesterone preparations in hormone replacement therapy cycles in assisted reproduction.
Full Text
About the authors
Nadezda V. Bashmakova
Urals Scientific Research Institute for Maternal and Child Care, Ministry of Health of Russia
Author for correspondence.
Email: BashmakovaNV@niiomm.ru
SPIN-code: 9604-0089
Dr. Med. Sci., Professor, Honored Doctor of the Russian Federation, Head of the Department of Assisted Reproductive Technologies, Chief Obstetrician-Gynecologist of the Ural Federal District, Chief Researcher
Russian Federation, YekaterinburgAlexandra Yu. Khramtsova
Urals Scientific Research Institute for Maternal and Child Care, Ministry of Health of Russia
Email: aleksaxr@mail.ru
SPIN-code: 2467-5326
Scopus Author ID: 57214320389
PhD, Obstetrician-Gynecologist, Researcher, Department of Assisted Reproductive Technologies
Russian Federation, YekaterinburgEl'mira R. Dzhalilova
Urals Scientific Research Institute for Maternal and Child Care, Ministry of Health of Russia
Email: vip.dzhalilova2017@mail.ru
ORCID iD: 0000-0002-4965-6663
Obstetrician-Gynecologist, Department of Assisted Reproductive Technologies, Graduate Student
Russian Federation, YekaterinburgReferences
- Mumusoglu S., Polat M., Ozbek I.Y., Bozdag G., Papanikolaou E.G., Esteves S.C. et al. Preparation of the endometrium for frozen embryo transfer: a systematic review. Front. Endocrinol. (Lausanne). 2021; 12: 688237. https://dx.doi.org/10.3389/fendo.2021.688237.
- Перминова С.Г., Савостина Г.В., Екимов А.Н., Белова И.С. Роль преимплантационного генетического тестирования эмбрионов на анеуплоидии в исходах программ вспомогательных репродуктивных технологий у различных групп пациентов. Акушерство и гинекология. 2023; 3: 73-82. [Perminova S.G., Savostina G.V., Ekimov A.N., Belova I.S. Role of preimplantation genetic testing of embryos for aneuploidy in assisted reproductive technology outcomes in different groups of patients. Obstetrics and Gynecology. 2023; (3): 73-82. (in Russian)]. https://dx.doi.org/10.18565/aig.2022.288.
- Мелкозёрова О.А., Башмакова Н.В., Данькова И.В., Окулова Е.О. Репродуктивные и перинатальные исходы применения криотехнологий в программах экстракорпорального оплодотворения (обзор литературы). Проблемы репродукции. 2019; 25(3): 82 90. [Melkozerova O.A., Bashmakova N.V., Dankova I.V., Okulova E.O. Reproductive and perinatal outcomes of a frozen embryo transfer in the programs of assisted reproductive technologies (literature review). Russian Journal of Human Reproduction. 2019; 25(3): 82 90. (in Russian)]. https://dx.doi.org/10.17116/repro20192503182.
- De Geyter C., Wyns C., Calhaz-Jorge C., de Mouzon J., Ferraretti A.P., Kupka M. et al. 20 Years of the european IVF-monitoring consortium registry: what have we learned? A comparison with registries from two other regions. Hum. Reprod. 2020; 35(12): 2832-49. https://dx.doi.org/10.1093/humrep/deaa250.
- Child T., Leonard S.A., Evans J.S., Lass A. Systematic review of the clinical efficacy of vaginal progesterone for luteal phase support in assisted reproductive technology cycles. Reprod. Biomed. Online. 2018; 36(6): 630-45. https://dx.doi.org/10.1016/j.rbmo.2018.02.001.
- Cicinelli E., de Ziegler D., Morgese S., Bulletti C., Luisi D., Schonauer L.M. “First uterine pass effect” is observed when estradiol is placed in the upper but not lower third of the vagina. Fertil. Steril. 2004; 81(5): 1414-6. https://dx.doi.org/10.1016/j.fertnstert.2003.12.016.
- Vaisbuch E., Leong M., Shoham Z. Progesterone support in IVF: is evidence-based medicine translated to clinical practice? A worldwide web-based survey. Reprod. Biomed. Online. 2012; 25(2): 139-45. https://dx.doi.org/10.1016/ j.rbmo.2012.04.005.
- Мальцева Л.И., Никогосян Д.М. Эффективность микронизированного прогестерона для профилактики невынашивания беременности. Гинекология. 2015; 17(2): 56-9. [Maltseva L.I., Nikogosyan D.M. Effectiveness of micronized progesterone for the prevention of miscarriage. Gynecology. 2015; 17(2): 56-9. (in Russian)].
- Булгакова В.П., Боровиков И.О. Применение препаратов микронизированного натурального прогестерона при подготовке к проведению вспомогательных репродуктивных технологий у пациенток с маточным фактором бесплодия. Проблемы репродукции. 2018; 24(6): 67 75. [Bulgakova V.P., Borovikov I.O. Use of micronized natural progesterone as preparation for assisted reproductive technologies in patients with uterine infertility factor. Russian Journal of Human Reproduction. 2018; 24(6): 67 75. (in Russian)]. https://dx.doi.org/10.17116/ repro20182406167.
- Pabuçcu E., Pabuçcu R., Gürgan T., Tavmergen E. Luteal phase support in fresh and frozen embryo transfer cycles. J. Gynecol. Obstet. Hum. Reprod. 2020; Jun 22:101838.https://dx.doi.org/10.1016/j.jogoh.2020.101838.
- Аполихина И.А., Тарнаева Л.А., Кондратьева Н.Е. Результаты исследований биоэквивалентности препаратов диеногеста, прогестерона, левоноргестрела+эстрадиол у здоровых добровольцев после однократного приема натощак. Акушерство и гинекология. 2023; 1: 110-21. [Apolikhina I.A., Tarnaeva L.A., Kondratyeva N.E. Results of bioequivalence studies on dienogest, progesterone, and levonorgestrel+estradiol in healthy volunteers after single dose intake during fasting. Obstetrics and Gynecology. 2023; (1): 110-21. (in Russian)]. https://dx.doi.org/10.18565/aig.2022.304.
Supplementary files
